Evidence map›Paper›PMID 38012091›Full record

ArticleHuman vaccines & immunotherapeutics2023

The functionality of a therapeutic antibody candidate restored by a single mutation from proline to threonine in the variable region.

Marie Hautiere, Irene Maffucci, Narciso Costa, Amaury Herbet, Sosthene Essono, Séverine Padiolleau-Lefevre, Didier Boquet

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marie HautiereDépartement Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris-Saclay, CEA, Gif-sur-Yvette, France.ORCID 0009-0002-7738-9459
Irene MaffucciCentre de Recherche de Royallieu, CNRS UMR 7025, Génie Enzymatique et Cellulaire, Compiègne Cedex, France.ORCID 0000-0002-4524-1137
Narciso CostaDépartement Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris-Saclay, CEA, Gif-sur-Yvette, France.ORCID 0000-0001-5730-8151
Amaury HerbetDépartement Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris-Saclay, CEA, Gif-sur-Yvette, France.ORCID 0000-0002-2142-0966
Sosthene EssonoMedical Biotechnology Engineering LLC, Malden, MA, USA.ORCID 0000-0003-0230-3585
Séverine Padiolleau-LefevreCentre de Recherche de Royallieu, CNRS UMR 7025, Génie Enzymatique et Cellulaire, Compiègne Cedex, France.ORCID 0000-0002-5475-1358
Didier BoquetDépartement Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris-Saclay, CEA, Gif-sur-Yvette, France.ORCID 0000-0002-4048-7867
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversité de Technologie de Compiègne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mAbs play an essential role in the therapeutic arsenal. Our laboratory has patented the Rendomab-B49 mAb targeting the endothelin B receptor (ET

Indexed as

Antibodies, MonoclonalThreonineMutationAntibodies, MonoclonalThreoninechimerizationin silico modellingMonoclonal antibodyproline

Identifiers

PMID38012091
PMCPMC10760395
OpenAlexW4389068450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.